Trial Profile
A study investigating if brentuximab-vedotin could normalize the fluorodeoxyglucose positron emission tomography status in platinum refractory Hodgkin lymphoma patients prior to high-dose therapy and autologous stem cell transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 14 Oct 2016 New trial record